The therapeutic advantage of combination antihypertensive drug therapy using amlodipine and irbesartan in hypertensive patients: Analysis of the post-marketing survey data from PARTNER (Practical combination therapy of Amlodin and angiotensin II Receptor blocker; safety and efficacy in patients with hypertension) study

References

• Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 2014;37:253–387
   PubMed Web of Science ®Google Scholar
• Mori H, Ukai H, Yamamoto H, et al. Current status of antihypertensive prescription and associated blood pressure control in Japan. Hypertens Res 2006;29:143–51
   PubMed Web of Science ®Google Scholar
• Ohkubo T, Obara T, Funahashi J, et al. Control of blood pressure as measured at home and office, and comparison with physicians’ assessment of control among treated hypertensive patients in Japan: first report of the Japan home versus office blood pressure measurement evaluation (J-HOME) study. Hypertens Res 2004;27:755–63
   PubMed Web of Science ®Google Scholar
• Armario P, Waeber B. Therapeutic strategies to improve control of hypertension. J Hypertens 2013;31:S9–12
   PubMed Web of Science ®Google Scholar
• Ishimitsu T, Minami J, Kawano Y, et al. Amlodipine, a long-acting calcium channel blocker, attenuates morning blood pressure rise in hypertensive patients. Clin Exp Pharmacol Physiol 1999;26:500–4
   PubMed Web of Science ®Google Scholar
• Ishimitsu T, Minami J, Yoshii M, et al. Comparison of the effects of amlodipine and losartan on 24-hour ambulatory blood pressure in hypertensive patients. Clin Exp Hypertens 2002;24:41–50
   PubMed Web of Science ®Google Scholar
• Agabiti-Rosei E, Muiesan ML, Rizzoni D, et al. Cardiovascular structural changes and calcium antagonist therapy in patients with hypertension. J Cardiovasc Pharmacol 1994;24:S37–43
   PubMed Web of Science ®Google Scholar
• Croom KF, Plosker GL. Irbesartan A review of its use in hypertension and diabetic nephropathy. Drugs 2008;68:1543–69
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–60
   PubMed Web of Science ®Google Scholar
• Parving HH, Lehnert H, Mortensen JB, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870–8
   PubMed Web of Science ®Google Scholar
• Ishimitsu T, Fukuda H, Uchida M, et al. Interim report on the PARTNER Study: practical combination therapy of amlodipine and angiotensin II receptor blocker; safety and efficacy in patients with hypertension. J Blood Press 2013;20:70–82
   Google Scholar
• Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982–92
   PubMed Web of Science ®Google Scholar
• Shimada K, Komuro I, Matsubara H, et al. Study of efficacy and safety of irbesartan/amlodipine combination therapy in hypertensive patients uncontrolled on irbesartan or amlodipine monotherapy. J Blood Press 2011;18:1231–43
   Google Scholar
• Fukuda H, Nishimura K, Uchida M, et al. The safety and efficacy of amlodipine in Japanese elderly hypertensive patients. J New Rem Clin 2011;60:1162–88
   Google Scholar
• Makani H, Bangalore S, Romero J, et al. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med 2011;124:128–35
   PubMed Web of Science ®Google Scholar
• Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296–305
   PubMed Web of Science ®Google Scholar
• Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375:2073–81
   PubMed Web of Science ®Google Scholar
• Anderson S. Antihypertensive therapy and the progression of renal disease. J Hypertens Suppl 1989;7:S39–42
   PubMedGoogle Scholar
• Hilgers KF, Mann JF. Role of angiotensin II in glomerular injury: lessons from experimental and clinical studies. Kidney Blood Press Res 1996;19:254–62
   PubMed Web of Science ®Google Scholar
• Ishimitsu T, Akashiba A, Kameda T, et al. Benazepril slows progression of renal dysfunction in patients with non-diabetic renal disease. Nephrology 2007;12:294–8
   PubMed Web of Science ®Google Scholar
• Ishimitsu T, Kameda T, Akashiba A, et al. Effects of valsartan on the progression of chronic renal insufficiency in patients with nondiabetic renal diseases. Hypertens Res 2005;28:865–70
   PubMed Web of Science ®Google Scholar
• Naritomi H, Fujita T, Ito S, et al. Efficacy and safety of long-term losartan therapy demonstrated by a prospective observational study in Japanese patients with hypertension: the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study. Hypertens Res 2008;31:295–304
   PubMed Web of Science ®Google Scholar
• Burnier M, Roch-Ramel F, Brunner HR. Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int 1996;49:1787–90
   PubMed Web of Science ®Google Scholar
• Wuerzner G, Burnier M. Effects of selective angiotensin II and beta1-receptor blockade on renal haemodynamics and sodium handling during orthostatic stress in healthy individuals. J Hypertens Suppl 2006;24:S89–93
   PubMedGoogle Scholar
• Palmer BF. Renal dysfunction complicating the treatment of hypertension. N Engl J Med 2002;347:1256–61
   PubMed Web of Science ®Google Scholar
• Nakamura M, Anzai N, Jutabha P, et al. Concentration-dependent inhibitory effect of Irbesartan on renal uric acid transporters. J Pharmacol Sci 2010;114:115–18
   PubMed Web of Science ®Google Scholar
• Thulin T. Calcium antagonists – assessment of side effects. Scand J Prim Health Care Suppl 1990;1:81–4
   PubMedGoogle Scholar
• Lee HY1, Kang HJ, Koo BK, et al. Clinic blood pressure responses to two amlodipine salt formulations, adipate and besylate, in adult Korean patients with mild to moderate hypertension: a multicenter, randomized, double-blind, parallel-group, 8-week comparison. Clin Ther 2005;27:728–39
   PubMed Web of Science ®Google Scholar
• Alderman MH, Cohen H, Madhavan S, Kivlighn S. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999;34:144–50
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Schillaci G, Reboldi G, et al. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 2000;36:1072–8
   PubMed Web of Science ®Google Scholar
• Iwashima Y, Horio T, Kamide K, et al. Uric acid, left ventricular mass index, and risk of cardiovascular disease in essential hypertension. Hypertension 2006;47:195–202
   PubMed Web of Science ®Google Scholar
• Franse LV, Pahor M, Di Bari M, et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000;18:1149–54
   PubMed Web of Science ®Google Scholar